La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
DMK Pharmaceuticals Gestione
Gestione criteri di controllo 0/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Eddie Glover
Amministratore delegato
n/a
Compenso totale
Percentuale dello stipendio del CEO | n/a |
Mandato del CEO | no data |
Proprietà del CEO | n/a |
Durata media del management | Nessun dato |
Durata media del Consiglio di amministrazione | Nessun dato |
Aggiornamenti recenti sulla gestione
Recent updates
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure
Sep 30Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.
Jul 29Adamis CEO urges stock split approval, slate of directors in letter to shareholders
Jul 21Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope
Apr 13Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic
Jan 20Adamis Pharmaceuticals: It's Now Or Never
Dec 02Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines
Sep 03Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares
Jun 13Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19
Jun 07Adamis pharmaceuticals gets deficiency letter from NASDAQ
May 28Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering
Jan 29Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose
Nov 16Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue
Nov 09AMMINISTRATORE DELEGATO
Eddie Glover (74 yo)
no data
Mandato
Mr. Eddie Wabern Glover serves as Chief Executive Officer of US Compounding Inc at DMK Pharmaceuticals Corporation (formerly known as Adamis Pharmaceuticals Corporation). He co-founded US Compounding, Inc....